PureIMS receives a grant of € 41.028,58 to initiate the development of a new dry powder inhaler (DPI). This new DPI will contain an innovative dispersion mechanism to enable delivery of medicines such as antibiotics, vaccines, and biologics. Unlike current devices, it will be user-friendly and suitable for vulnerable groups like children and elderly […]
Full paper: Pharmaceutics 2025, 17(9), 1149; https://doi.org/10.3390/pharmaceutics17091149 Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These […]
Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com
